TY - JOUR
T1 - Liraglutide in the treatment of Type 2 diabetes: Clinical data and practical considerations for its use
AU - Ampudia-Blasco, Francisco Javier
AU - Gmez, Carlos Calvo
AU - Claramunt, Xavier Cos
AU - Alegra, Javier Garca
AU - Gimeno, Esteban Jdar
AU - Bravo, José Javier Mediavilla
AU - Raya, Pedro Mezquita
AU - Pérez, Jorge Navarro
AU - Domingo, Manel Puig
PY - 2010/11/1
Y1 - 2010/11/1
N2 - Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. © 2010 Expert Reviews Ltd.
AB - Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. © 2010 Expert Reviews Ltd.
KW - GLP-1 analog
KW - glycemic control
KW - incretin
KW - liraglutide
KW - Type 2 diabetes mellitus
UR - https://www.scopus.com/pages/publications/78649352834
U2 - 10.1586/eem.10.59
DO - 10.1586/eem.10.59
M3 - Review article
SN - 1744-6651
VL - 5
SP - 799
EP - 807
JO - Expert Review of Endocrinology and Metabolism
JF - Expert Review of Endocrinology and Metabolism
IS - 6
ER -
